Drug Trial Radar · NCT02321800
A Study of Efficacy and Safety of Intravenous Cefiderocol (S-649266) Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections
Last checked: Nov 20, 2026Latest source record: Dec 12, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
452
Actual
Start
Feb 5, 2015
Primary completion
Jul 26, 2016
Study completion Aug 16, 2016
Sponsor
- Lead sponsor
- ShionogiIndustry
- Sponsor type
- Industry
- First posted
- Dec 22, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to determine the efficacy and safety of intravenous cefiderocol (S-649266) in hospitalized adults with complicated urinary tract infections caused by Gram-negative pathogens.
Conditions
- Urinary Tract Infections
Interventions
CefiderocolDrug
2000 mg intravenously every 8 hours for 7 to 14 days; dose adjustments for participants with reduced renal function (estimated CrCl ≤ 70 mL/minute) and/or body weight (\< 70 kg) included every 6-hour dosing intervals and/or reduced doses.
Imipenem/cilastatinDrug
1000 mg of each intravenously every 8 hours for 7 to 14 days; dose adjustments for participants with reduced renal function (estimated CrCl ≤ 70 mL/minute) and/or body weight (\< 70 kg) included every 6-hour dosing intervals and/or reduced doses.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Test of CureTime frame: Test of cure (TOC; 7 days after end of treatment [EOT], equivalent to Study Day 14 to 21)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.